

## **Júlio Oliveira**

Júlio Oliveira concluded his graduation in Medicine at the Instituto de Ciências Biomédicas de Abel Salazar – Porto University (ICBAS-UP), in 2003. Since 2011 he is Medical Oncologist at IPO Porto.

In 2017 he specialized in Clinical Pharmacology. At present time he is developing a PhD project in the area of Immuno-Oncology (ICBAS-UP).

Júlio Oliveira was vice-president of Associação Portuguesa de Investigação em Cancro (ASPIC) and was presidente of fiscal board of Sociedade Portuguesa de Oncologia (SPO).

In 2019 Júlio Oliveira created and become responsible for the Early Phase Clinical Trials Unit of IPO Porto, the first phase 1 unit dedicated to Oncology in Portugal. He was Principal Investigator (PI) responsible for several phase I-III clinical trials in breast and lung cancer, phase I clinical trials in solid tumors and translational research projects focusing on cancer biomarkers. He also coordinated an innovative program in the field of genomics, the Precision Oncology Program (POP-IPOP) and the Molecular Tumor Board of IPO Porto.

Also, as PI, he is developing a phase Ib/II investigator initiated clinical trial aiming to study the role of neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).

As co-investigator, Júlio Oliveira is developing the phase I clinical trial, first-in-human, with the first cancer treatment developed in Portugal.

Since October 2022 Júlio Oliveira is the Board President of IPO Porto.